Novartis to collaborate with Borisy's new biotech; AMRI inks pact with Genentech; Satori raises cash;

@FierceBiotech: Inspire shares tank after lead CF drug fails Ph3. Story | Follow @FierceBiotech

@JohnCFierce: New drug approvals are low. Favre says he will retire. Some things never change. Follow @JohnCFierce

> Alexis Borisy's new biotech company, Foundation Medicine, has inked a deal to collaborate with Novartis. Foundation will adapt its genome based tests for use with Novartis' medications. "This pilot collaboration with Novartis represents our first pharmaceutical partnership, and we are delighted to accomplish this important milestone with one of the world's leading cancer therapeutic companies," said Borisy. Story

> AMRI has forged a research and licensing pact with Genentech for a family of antibacterial compounds. Genentech will receive an exclusive license to develop and commercialize multiple potential products from AMRI's antibacterial program and AMRI will collaborate with Genentech in a research program with the objective of identifying novel antibacterial agents. AMRI release

> Cambridge, MA-based Satori Pharmaceuticals has raised $7 million, part of a $22 million round. Story

> Las Vegas-based CardioVascular BioTherapeutics released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds. Data indicates that "CVBT's FGF-1 biological drug appears to be delivering efficacy at a level significantly greater than has been seen in any other treatments, for patients suffering from chronic ischemic diabetic wounds." CVBT release

> BioMed Realty Trust of San Diego has paid close to $15 million for life sciences facilities in buildings in Durham and in Cary. Report

And Finally... The Wall Street Journal chronicles the work of Eisai researchers who found a lethal agent in nature that was recently approved to treat late-stage breast cancer. Story

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.